Clinical Study of Filtek™ Bulk Fill Posterior Restorative in Class I and II Restorations
Launched by 3M · Dec 3, 2018
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
This was a randomized, two- arm, non-inferiority study to evaluate the safety and clinical performance of resin composite, Filtek™ Bulk Fill.
Test apparatus: Apparatus for Test: Filtek™ Bulk Fill Posterior Restorative Apparatus for Control: 3M™ ESPE™ Filtek™ Z350XT, was approved by CFDA in 2010 and had been in the market for 5 years with some validated clinical data.
Sample Size of Subjects: Two-hundred forty (240) patients were expected to be recruited into the study and were randomly assigned to the test group and the control group according to the ratio of 1: 1; thus the number of case...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female,18 to 70 years old (including 18 and 70 years)
- • 2. Good health, no significant systemic disease;
- • 3. Normal opening degree;
- • 4. Molar (preferred) or premolar teeth
- • 5. Cavity type with belongs to any of the following: 1) Class I, including the failed class I restoration which require to be repaired.; 2) Class II, including premolar and molar except the second molar (the failed class II restoration which require to be repaired is also included), and the gingival wall of cavity is above the free gingival margin coronally; 3) Class II cavity on the second molar when the third molar exists, and the gingival wall of cavity is above the free gingival margin coronally; 4) Class II, MO or MOD cavity on the second molar when the third molar does not exist (the failed class II restoration which require to be repaired is also included), and the gingival wall of cavity is above the free gingival margin coronally;
- • 6. Cavity size: the buccolingual diameter of cavity is no less than the 1/3 and of the buccolingual cusp distance;
- • 7. Occlusion with natural teeth;
- • 8. Cavity depth: no less than 1/2 of dentin with a normal pulp status;
- • 9. Be able to understand informed consent and to provide written inform consent ;
- • 10. Be in good compliance with the protocol and willing to return to the site for follow up visits .
- Exclusion Criteria:
- • 1. Allergy to multiple medicines; allergy to resin or other polymer material;
- • 2. Acute caries, severe periodontitis, salivary glands malfunction, dysfunction/disorder of TMJ (temporomandibular joint);
- • 3. Poor oral hygiene, DMTF:18-34y \>4, 35-70y \>5;
- • 4. Teeth with abnormal staining ;
- • 5. Pathological abrasion (e.g. bruxism, clenching), acid corrosion, cracked-teeth and other non-caries diseases.
- • 6. Abnormal occlusion;
- • 7. Severe systemic or mental disorders;
- • 8. Pregnant or intended to be pregnant (pregnant test is positive ) or breast feeding women;
- • 9. Cavity do not meet the criteria based on the investigator's judgement;
- • 10. Resin Composite is not an appropriate restoration for the subject
- • 11. Pulp exposure or bottom of cavity is nearly close to the pulp;
- • 12. Subjects who is not able to return for the one year follow-up visit because of going abroad or other reasons;
- • 13. Subject is enrolled in other studies on investigational drug or device
- • 14. Cannot tolerate rubber dam isolation. -
Trial Officials
Xiaoyan Wang, Director
Principal Investigator
Endodontics department of Peking University hospital of stomatology
About 3m
3M is a globally recognized innovation company that leverages science and technology to develop a diverse range of products and solutions across multiple sectors, including healthcare, consumer goods, and industrial applications. With a commitment to improving lives through innovative research and development, 3M actively sponsors clinical trials to evaluate the safety and efficacy of its medical products and technologies. The company's extensive expertise in materials science and a collaborative approach to healthcare challenges position it at the forefront of advancing patient care and outcomes. Through rigorous clinical research, 3M aims to contribute meaningful advancements to medical practice and enhance the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Wuhan, Hubei, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials